2023 International Conference on Climate Resilient Pakistan

Celyad Oncology reports third quarter 2023 financial results and recent business highlights

Retrieved on: 
Thursday, November 9, 2023

“Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.

Key Points: 
  • “Celyad Oncology team is resolutely dedicated to harnessing our expertise, extensive know-how, and valuable intellectual property portfolio to address the existing challenges within CAR T-cell therapies.
  • Celyad Oncology has relocated from September 25, 2023 into a new research facility which fits better its current needs after the strategic shift.
  • The Company remains headquartered at the Axis Parc, Mont-Saint-Guibert, Belgium but with its new business location at Dumont 9.
  • Net cash burn during the third quarter of 2023 amounted to €2.7 million, in line with expectations.

Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, November 2, 2023

Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.

Key Points: 
  • Results of nonclinical toxicology study on-track to be submitted to the FDA by the end of 2023.
  • R&D expenses were €18.5 million for the quarter ended September 30, 2023, compared to €14.1 million for the quarter ended September 30, 2022.
  • G&A expenses were €7.7 million for the quarter ended September 30, 2023, compared to €8.3 million for the quarter ended September 30, 2022.
  • Details are as follows:
    Pharvaris is a Foreign Private Issuer and prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the International Accounting Standards Board.

Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress

Retrieved on: 
Thursday, August 10, 2023

AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.

Key Points: 
  • AFM24 combinations: Affimed plans to report data from the combination with atezolizumab in the fourth quarter 2023; data from combination study with SNK01 were presented at ASCO Breakthrough.
  • HEIDELBERG, Germany, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the second quarter of 2023.
  • Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB.
  • Affimed will host a conference call and webcast on August 10, 2023, at 8:30 a.m. EDT / 14:30 CET to discuss second quarter 2023 financial results and corporate developments.

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Retrieved on: 
Wednesday, August 2, 2023

Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.

Key Points: 
  • Research and development expenses were $62.0 million for the second quarter of 2023, which includes $6.9 million of non-cash stock-based compensation expense.
  • General and administrative expenses were $18.5 million for the second quarter of 2023, which includes $9.7 million of non-cash stock-based compensation expense.
  • Net loss for the second quarter of 2023 was $78.0 million, or $0.53 per share, including non-cash stock-based compensation expense of $16.6 million.
  • Allogene will host a live conference call and webcast today at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss financial results and provide a business update.

Global Internal Audit Leaders Leave IIA 2023 International Conference with Focus on the Future

Retrieved on: 
Thursday, July 13, 2023

AMSTERDAM, July 13, 2023 /PRNewswire/ -- The Institute of Internal Auditors (IIA) - the internal audit profession's leader in standards, certifications, education, research, and technical guidance worldwide – today concluded its 2023 International Conference, the premier global internal audit event of the year.

Key Points: 
  • Premier global internal audit event spotlights Vision 2035 project, global risk research, preliminary feedback on new proposed Global Internal Audit Standards, and how to respond to rapid change.
  • AMSTERDAM, July 13, 2023 /PRNewswire/ -- The Institute of Internal Auditors (IIA) - the internal audit profession's leader in standards, certifications, education, research, and technical guidance worldwide – today concluded its 2023 International Conference, the premier global internal audit event of the year.
  • The Standards Board expects to release the new Global Internal Audit Standards™ before the end of 2023.
  • Pugliese updated attendees on the Internal Audit: Vision 2035 project, which is led by the Internal Audit Foundation.

ExThera Medical Exhibits at the 2023 International Conference on Extracorporeal Organ Support in Zagreb, Croatia

Retrieved on: 
Tuesday, June 6, 2023

ExThera Medical, a healthcare company that has developed and commercialized a unique extracorporeal blood filtration medical device, participated in the annual International Conference on Extracorporeal Organ Support.

Key Points: 
  • ExThera Medical, a healthcare company that has developed and commercialized a unique extracorporeal blood filtration medical device, participated in the annual International Conference on Extracorporeal Organ Support.
  • Throughout the conference, the Seraph® 100 MicroBind® Affinity Blood Filter was featured as a therapy with established clinical utility for broad bacterial, viral, and fungal pathogen removal, with academic faculty presentations highlighting published data and successful patient treatments therein.
  • There is a lot of potential for the Seraph 100 to prove itself in rigorous clinical trials,” said Thomas Rimmele, MD, and conference faculty.
  • Additional presentations featured during the May 4-6 conference focused on the clinical efficacy and implementation of Seraph 100 for the purpose of treating critically ill patients suffering from bloodstream infections.

Council on Tall Buildings and Urban Habitat Reveals Exemplary Projects in Sustainable Vertical Urbanism Across the Globe

Retrieved on: 
Wednesday, May 31, 2023

Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The Council on Tall Buildings and Urban Habitat (CTBUH) announced today its 2023 Award of Excellence winners, with over 100 of the year’s most exemplary projects in sustainable vertical urbanism.

Key Points: 
  • Chicago, IL, May 31, 2023 (GLOBE NEWSWIRE) -- The Council on Tall Buildings and Urban Habitat (CTBUH) announced today its 2023 Award of Excellence winners, with over 100 of the year’s most exemplary projects in sustainable vertical urbanism.
  • Projects from across the globe were recognized in more than 20 categories and subcategories, including Best Tall Building, Best Tall Non-building, Innovation, Urban Habitat, Repositioning and Equity, Diversity & Inclusion, a new category in 2023.
  • Only then can we support balanced and healthy living, working and civic and social engagement,” continued Quintana de Uña.
  • The Council on Tall Buildings and Urban Habitat (CTBUH) is the world’s leading resource for professionals focused on the inception, design, construction, and operation of tall buildings and future cities.

Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

Retrieved on: 
Monday, May 22, 2023

Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.

Key Points: 
  • Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients with idiopathic pulmonary fibrosis.
  • Pulmonary fibrosis is a devastating, life-threatening illness, with daily symptoms including coughing, labored breathing and extreme fatigue.
  • Dose reductions due to blood pressure criteria were implemented in 5% (placebo), 8% (30 mg) and 6% (60 mg) of patients.
  • A similar number of patients received dose reduction across the placebo (n=5), 30 mg (n=7) and 60 mg (n=6) treatment arms.

Median Technologies Reports Full-year 2022 Results and Business Indicators for the First Quarter Of 2023

Retrieved on: 
Thursday, April 20, 2023

Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.

Key Points: 
  • Median Technologies (Euronext Growth - ALMDT) (Paris;ALMDT) whose Board of Directors met on April 19, 2023 to approve the consolidated financial statements for the financial year ending December 31, 2022, today announces its full-year results for 2022 and business indicators (unaudited) for the first quarter of 2023.
  • In the first quarter of 2023, we achieved revenue of €5.6 million, with an order backlog of €62 million at March 31.
  • In March 2023 , Median Technologies presented new results for the performance of its iBiopsy® LCS CADe/CADx SaMD.
  • On January 19, 2023 , Median reported business indicators for 2022 and now confirms the following audited figures:
    An order backlog at December 31, 2022 of €60.8 million;
    Cash and cash equivalents of €21.5 million at December 31, 2022.

LI.FI raises $17.5 million Series A to help traditional finance build on DeFi

Retrieved on: 
Monday, April 3, 2023

BERLIN, April 3, 2023 /PRNewswire/ -- LI.FI, the leading multi-chain liquidity and data gateway, announced today that it has raised more than $17 million in a Series A fundraise co-led by CoinFund and Superscrypt.

Key Points: 
  • The round, which totalled $17.5 million, also includes participation from Bloccelerate , L1 Digital , Circle , Factor , Perridon , Theta Capital , Three Point Capital , Abra , and nearly 20 angel investors.
  • "This fundraise is vital to enabling us to execute our vision of a multi-chain future," said Philipp Zentner, CEO at LI.FI. "
  • "LiFi has a unique position as not only the go-to place for consumers for cross-chain transactions, but also the first stop for developers and traditional financial institutions.
  • This framework was created in collaboration with ConsenSys, with a goal of providing a general toolkit for reasoning about cross-chain protocols.